首页> 外文期刊>海南医科大学学报(英文版) >Clinical efficacy and significance of serum fibroblast growth factor-21 and ghrelin in the treatment of type 2 diabetes complicated with coronary heart disease with integrated traditional Chinese and western medicine
【24h】

Clinical efficacy and significance of serum fibroblast growth factor-21 and ghrelin in the treatment of type 2 diabetes complicated with coronary heart disease with integrated traditional Chinese and western medicine

机译:血清成纤维细胞生长因子-21和生长素释放肽在中西医结合治疗2型糖尿病合并冠心病中的临床疗效及意义

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To treat the patients with type 2 diabetes mellitus complicated with coronary heart disease, to explore the clinical efficacy and mechanism of conventional western medicine combined with Yiqi Yangyin Huoxue herbs, and to detect the level of serum fibroblast growth factor-21 (FGF-21) and Ghrelin. Changes and significance. Methods: A randomized control method was used to collect 100 patients with type 2 diabetes mellitus complicated with coronary heart disease who were diagnosed and treated in our hospital from March 2015 to March 2018.They were randomly divided into two groups according to the random number table method: 50 patients separately. The patients in the control group were treated with conventional western medicine and basic treatment; the observation group was treated with the addition and subtraction of traditional Chinese medicine formulas on the basis of the control group; the clinical curative effect was evaluated after two months of treatment, and the treatment efficiency and scores of traditional Chinese medicine symptoms were observed in the two groups. Basic laboratory indicators were improved, and serum levels of FGF-21 and Ghrelin in patients were measured and the difference between the results of the tests was compared with the condition and efficacy. Results: After treatment, the total effective rate of the observation group (86.0%) was significantly higher than that of the control group (68.0%) (P<0.05), suggesting that the combination of Chinese and Western medicine treatment can significantly improve the clinical efficacy; before treatment,there is no difference between the two groups of Chinese medicine symptom scores (P>0.05). After treatment, the symptom scores of the two groups were significantly improved after treatment (P<0.05). The observation group was better among the two groups (P<0.05).After treatment, the basic biochemical indicators were improved. The observation group was better than the control group (P<0.05);Serum FGF-21 levels were significantly lower in both groups after treatment (P<0.05), and Ghrelin levels were significantly increased. There was a statistically significant difference between the two groups (P<0.05). Conclusion: The use of conventional western medicine in combination with Yiqi Yangyin Huoxue Chinese medicine for the treatment of type 2 diabetes mellitus patients with coronary heart disease can significantly improve the clinical efficacy, effectively promote the improvement of symptoms, and can be used in clinical work through serum FGF-21, Ghrelin levels combined detection of the value of Abnormal changes to predict the severity of type 2 diabetes mellitus with coronary heart disease severity and treatment effect should be widely used in clinical diagnosis and treatment.
机译:目的:治疗2型糖尿病合并冠心病患者,探讨中西医结合益气养阴活血中药的临床疗效和作用机制,并检测血清成纤维细胞生长因子21(FGF- 21)和Ghrelin。变化和意义。方法:采用随机对照方法,收集我院2015年3月至2018年3月确诊并治疗的2型糖尿病合并冠心病患者100例,根据随机数字表随机分为两组。方法:50名患者分开。对照组患者均接受常规西药和基础治疗。观察组在对照组的基础上加减中药配方。治疗两个月后评价临床疗效,观察两组疗效及中药症状评分。改善了实验室的基本指标,测量了患者的血清FGF-21和Ghrelin的水平,并比较了测试结果与病情和疗效之间的差异。结果:治疗后观察组总有效率(86.0%)明显高于对照组(68.0%)(P <0.05),提示中西医结合治疗可显着改善治疗效果。临床疗效;治疗前两组中医症状评分无差异(P> 0.05)。治疗后,两组的症状评分明显改善(P <0.05)。观察组两组之间比较好(P <0.05)。治疗后基础生化指标得到改善。观察组优于对照组(P <0.05);两组治疗后血清FGF-21水平明显降低(P <0.05),Ghrelin水平明显升高。两组之间有统计学差异(P <0.05)。结论:传统西药结合益气养阴活血中药治疗2型糖尿病冠心病患者可明显提高临床疗效,有效促进症状改善,可用于临床工作通过血清FGF-21,Ghrelin水平联合检测值的异常变化来预测2型糖尿病的严重程度与冠心病的严重程度和治疗效果应在临床诊断和治疗中广泛应用。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2018年第22期|13-17|共5页
  • 作者单位

    Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, 110032, Liaoning Province, China;

    Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, 110032, Liaoning Province, China;

    Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, 110032, Liaoning Province, China;

    Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, 110000, Liaoning Province, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号